Abstract
At JADPRO Live 2024, J. Kevin Hicks, PharmD, PhD, FCCP, highlighted advances in targeted therapies, liquid biopsies, and genetic profiling to improve outcomes in patients. He discussed the impact of trials such as FLAURA2 and MARIPOSA on refining treatment for EGFR-mutated NSCLC and the use of pharmacogenomics to guide dosing. Dr. Hicks also described the creation of an innovative cloud-based platform at Moffitt Cancer Center designed to organize genetic testing data and streamline clinical decisions.
References
Cho, B. C., Lu, S., Felip, E., Spira, A. I., Girard, N., Lee, J. S., Lee, S. H., Ostapenko, Y., Danchaivijitr, P., Liu, B., Alip, A., Korbenfeld, E., Mourão Dias, J., Besse, B., Lee, K. H., Xiong, H., How, S. H., Cheng, Y., Chang, G. C., Yoshioka, H.,…MARIPOSA Investigators (2024). Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. The New England Journal of Medicine, 391(16), 1486–1498. https://doi.org/10.1056/NEJMoa2403614
Hicks, J. K., Quilitz, R. E., Komrokji, R. S., Kubal, T. E., Lancet, J. E., Pasikhova, Y., Qin, D., So, W., Caceres, G., Kelly, K., Salchert, Y. S., Shahbazian, K., Abbas-Aghababazadeh, F., Fridley, B. L., Velez, A. P., McLeod, H. L., & Greene, J. N. (2020). Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations. Clinical Pharmacology and Therapeutics, 107(3), 563–570. https://doi.org/10.1002/cpt.1641
Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D. Y., Banerjee, S., González-Martín, A., Jung, K. H., Ługowska, I., Manso, L., Manzano, A., Melichar, B., Siena, S., Stroyakovskiy, D., Fielding, A., Ma, Y., Puvvada, S., Shire, N., & Lee, J. Y. (2024). Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. Journal of Clinical Oncology, 42(1), 47–58. https://doi.org/10.1200/JCO.23.02005
Planchard, D., Jänne, P. A., Cheng, Y., Yang, J. C., Yanagitani, N., Kim, S. W., Sugawara, S., Yu, Y., Fan, Y., Geater, S. L., Laktionov, K., Lee, C. K., Valdiviezo, N., Ahmed, S., Maurel, J. M., Andrasina, I., Goldman, J., Ghiorghiu, D., Rukazenkov, Y., Todd, A.,…FLAURA2 Investigators (2023). Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. The New England Journal of Medicine, 389(21), 1935–1948. https://doi.org/10.1056/NEJMoa2306434
Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B. C., Cheng, Y., Cho, E. K., Voon, P. J., Planchard, D., Su, W. C., Gray, J. E., Lee, S. M., … FLAURA Investigators (2018). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. The New England journal of medicine, 378(2), 113–125. https://doi.org/10.1056/NEJMoa1713137
Wang, L., McLeod, H. L., & Weinshilboum, R. M. (2011). Genomics and drug response. The New England Journal of Medicine, 364(12), 1144–1153. https://doi.org/10.1056/NEJMra1010600
Zhou, C., Tang, K. J., Cho, B. C., Liu, B., Paz-Ares, L., Cheng, S., Kitazono, S., Thiagarajan, M., Goldman, J. W., Sabari, J. K., Sanborn, R. E., Mansfield, A. S., Hung, J. Y., Boyer, M., Popat, S., Mourão Dias, J., Felip, E., Majem, M., Gumus, M., Kim, S. W.,…PAPILLON Investigators (2023). Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. The New England Journal of Medicine, 389(22), 2039–2051. https://doi.org/10.1056/NEJMoa2306441
